Clinical Trial Update: A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D Mutation [Phase 1]

View source ↗

Summary

AstraZeneca's Phase I/IIa study of AZD0022 in KRASG12D-mutant tumors has been terminated. The study enrolled adults with advanced solid tumors, Non-Small Cell L…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Non-small Cell Lung Cancer
• Pancreatic Ductal Adenocarcinoma
• Solid Tumors

Drugs mentioned

• AZD0022

Snippet

Sponsor: AstraZeneca | Conditions: Advanced Solid Tumours, Non-Small Cell Lung Cancer (NSCLC) | Phase 1 | Status: TERMINATED